Postinduction therapy, transplantation, and long-term outcomes by treatment group
| . | Total (N = 100) . | VenAza (n = 44) . | ICH (n = 56) . | P value . |
|---|---|---|---|---|
| Subsequent therapy, n (%) | .002 | |||
| Second line | 22 (22) | 12 (27.3) | 10 (17.9) | |
| Cytarabine∗ | 26 (26) | 4 (9.1) | 22 (39.3) | |
| Venetoclax + Azacitidine | 8 (8) | 5 (11.4) | 3 (5.4) | |
| Consolidative HSCT | 8 (8) | 6 (13.6) | 2 (3.6) | |
| None | 32 (32) | 13 (29.5) | 19 (33.9) | |
| Palliative care | 4 (4) | 4 (9.1) | 0 (0) | |
| HSCT, n (%) | 31 (31) | 14 (31.8) | 17 (30.4) | .88 |
| Time to HSCT, median (range), d | 140 (43-421) | 112 (43-255) | 154 (57-421) | .34 |
| Long-term outcomes | ||||
| Relapse (n = 47), n (%) | 30 (63.8) | 6 (35.3) | 24 (80) | .002 |
| Time to relapse (n = 30), median (range), mo | 5.8 (1.6-53.1) | 5.9 (1.8-13.1) | 5.8 (1.6-53.1) | .68 |
| Event, n (%) | 82 (82) | 31 (70.5) | 51 (91.1) | .008 |
| Time to event (months) | 2.4 (0-54.4) | 2.5 (0-16.3) | 0 (0-54.4) | .92 |
| Death, n (%) | 67 (67) | 22 (50) | 45 (80.4) | .001 |
| Cause of death, n (%) | .55 | |||
| Treatment related | 27 (40.3) | 10 (45.5) | 17 (37.8) | |
| Disease related | 40 (59.7) | 12 (54.5) | 28 (62.2) |
| . | Total (N = 100) . | VenAza (n = 44) . | ICH (n = 56) . | P value . |
|---|---|---|---|---|
| Subsequent therapy, n (%) | .002 | |||
| Second line | 22 (22) | 12 (27.3) | 10 (17.9) | |
| Cytarabine∗ | 26 (26) | 4 (9.1) | 22 (39.3) | |
| Venetoclax + Azacitidine | 8 (8) | 5 (11.4) | 3 (5.4) | |
| Consolidative HSCT | 8 (8) | 6 (13.6) | 2 (3.6) | |
| None | 32 (32) | 13 (29.5) | 19 (33.9) | |
| Palliative care | 4 (4) | 4 (9.1) | 0 (0) | |
| HSCT, n (%) | 31 (31) | 14 (31.8) | 17 (30.4) | .88 |
| Time to HSCT, median (range), d | 140 (43-421) | 112 (43-255) | 154 (57-421) | .34 |
| Long-term outcomes | ||||
| Relapse (n = 47), n (%) | 30 (63.8) | 6 (35.3) | 24 (80) | .002 |
| Time to relapse (n = 30), median (range), mo | 5.8 (1.6-53.1) | 5.9 (1.8-13.1) | 5.8 (1.6-53.1) | .68 |
| Event, n (%) | 82 (82) | 31 (70.5) | 51 (91.1) | .008 |
| Time to event (months) | 2.4 (0-54.4) | 2.5 (0-16.3) | 0 (0-54.4) | .92 |
| Death, n (%) | 67 (67) | 22 (50) | 45 (80.4) | .001 |
| Cause of death, n (%) | .55 | |||
| Treatment related | 27 (40.3) | 10 (45.5) | 17 (37.8) | |
| Disease related | 40 (59.7) | 12 (54.5) | 28 (62.2) |
Bonferroni-adjusted post hoc analysis showed significant differences in this subgroup.